Lutris updates
News & Announcements
Updates on our clinical programs, corporate milestones, and financing.
Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-RAF inhibitors Including Lead Asset LUT014
Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients
Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 — a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions — in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy
Lutris Pharma Appoints Life Science Executive, Jack Weinstein, as Chairman of the Board of Directors
Israel's Lutris shares positive readout from early-stage trials of B-RAF inhibitor
Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery
Topical therapy can help safely reduce side effect of cancer treatment
Novel B-RAF-Inhibitor Cream Ameliorates Rash From EGFR Inhibitors
Side effect of cancer treatment can be safely reduced with topical cream